文献速递MDS 与骨髓增殖性肿瘤

真性红细胞增多症:历史疏漏、诊断细节与治疗观点

Polycythemia vera: historical oversights, diagnostic details, and therapeutic views.
PubMed 文献 · Leukemia · 2021-09-03

本文为特邀综述,讨论真性红细胞增多症(PV)的诊断、预后与治疗。PV为相对惰性的髓系肿瘤,年轻患者中位生存超过35年,但20年血栓、纤维化及白血病转化率分别为26%、16%、4%。当前治疗主要预防血栓并发症,而非延长生存或降低转化风险。

要点

  • 所有PV患者需放血使血细胞比容低于45%,并每日一次低剂量阿司匹林(无禁忌时)。
  • 高危(年龄>60岁或血栓史)或症状性低危患者推荐降细胞治疗,首选羟基脲。
  • 聚乙二醇干扰素可作为特定情况下的替代,如年轻育龄女性、羟基脲不耐受/抵抗者。

核心结论

  • 当前PV治疗旨在预防血栓并发症,未显示延长生存或降低白血病/纤维化进展风险。

研究设计与样本

  • 特邀综述,讨论PV诊断、预后及治疗,包括妊娠和内脏静脉血栓等特定情况。

主要发现

  • 年轻PV患者中位生存超过35年;20年血栓、纤维化及白血病转化率分别为26%、16%、4%。
  • PV风险分为高危(年龄>60岁或血栓史)和低危(两者均无)。

关键数值与推荐

  • 所有患者需放血使血细胞比容低于45%,并每日一次低剂量阿司匹林(无禁忌时)。
  • 降细胞治疗推荐用于高危或症状性低危患者;首选羟基脲,聚乙二醇干扰素为特定情况替代。
  • 其他选择包括白消安(老年患者首选)和芦可替尼(post-PV骨髓纤维化症状或顽固瘙痒时)。

临床怎么用

  • 根据年龄和血栓史进行风险分层,低危患者放血加阿司匹林,高危或症状性低危加降细胞治疗。
  • 羟基脲为一线降细胞药物,聚乙二醇干扰素用于年轻育龄女性、羟基脲不耐受/抵抗或为减少放血需求时。

局限性

  • 需对照研究明确每日两次vs一次阿司匹林及直接口服抗凝药的附加价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Polycythemia vera (PV) is a relatively indolent myeloid neoplasm with median survival that exceeds 35 years in young patients, but its natural history might be interrupted by thrombotic, fibrotic, or leukemic events, with respective 20-year rates of 26%, 16%, and 4%. Current treatment strategies in PV have not been shown to prolong survival or lessen the risk of leukemic or fibrotic progression and instead are directed at preventing thrombotic complications. In the latter regard, two risk categories are considered: high (age >60 years or thrombosis history) and low (absence of both risk factors). All patients require phlebotomy to keep hematocrit below 45% and once-daily low-dose aspirin, in the absence of contraindications. Cytoreductive therapy is recommended for high-risk or symptomatic low-risk disease; our first-line drug of choice in this regard is hydroxyurea but we consider pegylated interferon as an alternative in certain situations, including in young women of reproductive age, in patients manifesting intolerance or resistance to hydroxyurea therapy, and in situations where treatment is indicated for curbing phlebotomy requirement rather than preventing thrombosis. Additional treatment options include busulfan and ruxolitinib; the former is preferred in older patients and the latter in the presence of symptoms reminiscent of post-PV myelofibrosis or protracted pruritus. Our drug choices reflect our appreciation for long-term track record of safety, evidence for reduction of thrombosis risk, and broader suppression of myeloproliferation. Controlled studies are needed to clarify the added value of twice- vs once-daily aspirin dosing and direct oral anticoagulants. In this invited review, we discuss our current approach to diagnosis, prognostication, and treatment of PV in general, as well as during specific situations, including pregnancy and splanchnic vein thrombosis.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Tefferi A, Vannucchi AM, Barbui T, et al. Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. Leukemia. 2021. PMID: 34480106. doi:10.1038/s41375-021-01401-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。